• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Unproven Treatments

Background

Because there is no cure for ALS/MND, and approved treatments have a limited effect, people diagnosed with the disease may seek out options that are not offered by their physician. Determining the difference between true and false information regarding ALS treatments can be difficult.

The internet has many websites that promote effective ALS treatments for purchase. Often they are well designed, boast treatments available for multiple diseases and ailments, and provide reassurance through online testimonials from previous clients. In nearly all of these cases, there is no evidence of safety, and in none has a benefit been shown in rigorous scientific studies. Furthermore, these treatments are often extremely expensive, and they are marketed to people who are looking for options. Many people with ALS spend critical life savings or raise funds through family and friends for an opportunity to save their life.

Unproven treatments are sometimes called alternative or off-label treatments. Examples include, but are not limited to: stem cell clinics; holistic, naturopathic, homeopathic, and traditional medicine; and dietary or physical therapy regimens.

Resources like ALSUntangled can be valuable for balanced, open-access information about such alternative treatments, and ClinicalTrials.gov is a resource for determining whether a particular treatment is being tested in a legitimate clinical trial.

The ALSUntangled article “Ten red flags”—things to be wary of in alternative or off-label products—provides a helpful guide to the warning signs to look out for in an advertised potential treatment. Read the “Ten red flags” article.

Recommendation

The SAC recommends that Alliance members defer all medical advice regarding unapproved, unproven, or off-label treatments to an individual’s own clinician. This may be accompanied by objective information about the specific treatment, which may be provided by the SAC. Providing links to resources like ALSUntangled and clinical trials databases like ClinicalTrials.gov is encouraged. Accompanying information can be especially important in situations where an individual does not have access to an ALS specialist physician, and it may assist their clinician in making a medical recommendation. It can also be important to relay that there are thousands of researchers around the world who are dedicated to understanding ALS and finding effective treatments, and if there were anything, anywhere, that actually worked, we would know and we would do everything we could to get it to people living with the disease as soon as possible.

International Alliance of ALS/MND Associations
June 2020


The original language of communication is English, and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Advocacy

  • Advocacy Toolkit

  • Feng Gin Sun, China

    Feng Gin Sun, China

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Ana María Zavala, Mexico

    Ana María Zavala, Mexico

  • Carlos Gomez Matallanas, Spain

    Carlos Gomez Matallanas, Spain

  • Liz Ogg, Scotland

    Liz Ogg, Scotland

  • Danny Reviers, Belgium

    Danny Reviers, Belgium

  • Jon Newsome, USA

    Jon Newsome, USA

  • Peng Yi-Wen, Taiwan

    Peng Yi-Wen, Taiwan

  • Mirca Bersani, Italy

    Mirca Bersani, Italy
    MircaBersani

  • Kirsten Harley, Australia

    Kirsten Harley, Australia

  • Rosie Riley, USA

    Rosie Riley, USA

  • Guido De Mets, Belgium

    Guido De Mets, Belgium

  • Elkin Gaviria, Colombia

    Elkin Gaviria, Colombia

  • Joyce Rusinak, USA

    Joyce Rusinak, USA

  • Mahmood Anwar, UK

    Mahmood Anwar, UK

  • Margarita Pizarro, Argentina

    Margarita Pizarro, Argentina

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Elkin Ramiro Gaviria Muñoz, Colombia

    Elkin Ramiro Gaviria Muñoz, Colombia

  • Hiroshi Matsuyama, Japan

    Hiroshi Matsuyama, Japan

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Jorge Luis Fernández Romero, Mexico

    Jorge Luis Fernández Romero, Mexico

  • Shay Rishoni, Netherlands

    Shay Rishoni, Netherlands

  • Ailsa Malcolm-Hutton, UK

    Ailsa Malcolm-Hutton, UK

  • Josée Kolijn-de Man, Netherlands

    Josée Kolijn-de Man, Netherlands

  • Lin Yong Yi, Taiwan

    Lin Yong Yi, Taiwan

  • Len Johnrose, England

    Len Johnrose, England

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Maurice Leclerc, Canada

    Maurice Leclerc, Canada

  • Lachlan Terry, Australia

    Lachlan Terry, Australia

  • Jorge Melo, Brazil

    Jorge Melo, Brazil

  • Jack Buzby, USA

    Jack Buzby, USA

  • Eric Von Schaumburg, USA

    Eric Von Schaumburg, USA

  • Laurie Petit-Jean, France

    Laurie Petit-Jean, France

  • Horacio Fritzer, Argentina

    Horacio Fritzer, Argentina

  • Fabio Carvalho, Brazil

    Fabio Carvalho, Brazil

  • Stephanie Christiansen Hall, Canada

    Stephanie Christiansen Hall, Canada

  • Brigitte Wernli, Switzerland

    Brigitte Wernli, Switzerland

  • Anita Forte, USA

    Anita Forte, USA

  • Wendy Hendrickson, USA

    Wendy Hendrickson, USA

  • Frank Taylor, USA

    Frank Taylor, USA

  • Sanjay Kumar Srivastava, India

    Sanjay Kumar Srivastava, India

  • Mike Cels, Canada

    Mike Cels, Canada

  • Lombana, Spain

    Lombana, Spain

  • Yannick Richard, Canada

    Yannick Richard, Canada
    yannickrichard

  • Anna Barrow, UK

    Anna Barrow, UK

  • Anthony Lynch, Australia

    Anthony Lynch, Australia

  • Chen Chun-Chin, Malaysia

    Chen Chun-Chin, Malaysia

  • Irene McCaughey, Australia

    Irene McCaughey, Australia

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login